Validation of a novel genomic biomarker of mesenchymal stem cell scalability and implications of genotype status on cellular senescence phenotypes.

Ex vivo expansion impairs the regenerative potential of bone marrow-derived mesenchymal stem cells (BM-MSCs), primarily by inducing cellular senescence. Interestingly, populations of BM-MSCs that exhibit resistance to senescence even after prolonged expansion have been reported. However, a reliable strategy to identify these populations is still underway. Previously, the GSTT1 gene has been identified as a biomarker for BM-MSC scalability, but its effects on BM-MSC senescence have not yet been studied. Here, we investigate the role of GSTT1 genotype in BM-MSC senescence and proliferation. First, we categorized six BM-MSC groups into GSTT1 positive and GSTT1 negative groups based on their genotype. Then, we performed long-term in vitro culture and exposed cells to irradiation as senescence models. After that, their proliferative potential, SASP, and the expression of key genes were investigated. The results show that GSTT1 null BM-MSCs have a higher proliferative potential at low passages and exhibit fewer senescent cells in culture when compared to the other genotypes. Additionally, these cells exhibit a lower expression of p21 Waf1, p14ARF and IL-6, and a higher expression of ACTA2 throughout culture. A GSTT1 null genotype can serve as a potential biomarker to identify BM-MSC populations with higher resistance to senescence.